Patient Derived Cd19 Specific Car T Cells Also Expressing An Egfrt
CD19+ Acute Leukemia
Seattle Children's HospitalCell therapyPhase 1/2Active
CCC
48/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 33/ 100
- Competitive Position
- 95/ 100
Competitive context
59 Active assets in the CD19+ Acute Leukemia cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine Sawa Ito, MD | Phase 2/3 | BB |
Cyclophosphamide Sawa Ito, MD | Phase 4 | BB |
Cytosin-Arabinosid Janssen Research & Development, LLC | Phase 2/3 | BB |
METHOTREXATE SWOG Cancer Research Network | Phase 3 | BB |
ETOPOSIDE Nanfang Hospital, Southern Medical University | Phase 2/3 | BB |
View all 50 →
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →